Q1 Earnings Estimate for Immunome Issued By Lifesci Capital

Key Points

• Lifesci Capital has raised its Q1 2026 earnings per share (EPS) forecast for Immunome to ($0.73), slightly improving from a prior estimate of ($0.75). The company's full-year earnings consensus estimate stands at ($2.21) per share.
• Immunome reported a ($0.50) EPS for the latest quarter, exceeding consensus expectations by $0.02, with revenue reaching $4.02 million against anticipated $1.03 million.
• Analysts have varied ratings on Immunome, with an average price target of $23.14 and a consensus rating of "Moderate Buy," while other reports indicate a recent increase in institutional investment activity.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Research analysts at Lifesci Capital raised their Q1 2026 EPS estimates for shares of Immunome in a research report issued on Wednesday, August 6th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings per share of ($0.73) for the quarter, up from their prior forecast of ($0.75). The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q2 2026 earnings at ($0.73) EPS.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The firm had revenue of $4.02 million for the quarter, compared to analyst estimates of $1.03 million.

Several other equities research analysts have also commented on the stock. JPMorgan Chase & Co. decreased their target price on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Wedbush restated an "outperform" rating and set a $21.00 target price on shares of Immunome in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Immunome presently has a consensus rating of "Moderate Buy" and an average target price of $23.14.

Immunome Stock Down 0.6%

NASDAQ:IMNM traded down $0.06 during midday trading on Monday, reaching $9.95. The stock had a trading volume of 446,644 shares, compared to its average volume of 1,015,981. The stock has a market cap of $866.05 million, a P/E ratio of -3.23 and a beta of 1.93. Immunome has a 12-month low of $5.15 and a 12-month high of $16.73. The firm has a fifty day simple moving average of $9.59 and a two-hundred day simple moving average of $8.91.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in Immunome by 2,540.4% in the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock worth $6,888,000 after buying an additional 624,045 shares during the period. Wellington Management Group LLP increased its position in Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock worth $1,546,000 after buying an additional 4,874 shares during the period. Geode Capital Management LLC increased its position in Immunome by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company's stock worth $13,054,000 after buying an additional 21,396 shares during the period. Wells Fargo & Company MN increased its position in Immunome by 45.5% in the fourth quarter. Wells Fargo & Company MN now owns 26,207 shares of the company's stock worth $278,000 after buying an additional 8,190 shares during the period. Finally, Renaissance Technologies LLC increased its position in Immunome by 2,696.5% in the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock worth $3,356,000 after buying an additional 304,700 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime acquired 5,000 shares of the stock in a transaction on Tuesday, June 3rd. The stock was bought at an average price of $9.38 per share, with a total value of $46,900.00. Following the completion of the transaction, the director directly owned 36,415 shares of the company's stock, valued at $341,572.70. The trade was a 15.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.69% of the stock is owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.